news
Cellistic and Celyad Oncology announce GMP cell therapy manufacturing operations transaction
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
List view / Grid view
Induced Pluripotent Stem Cells (iPSCs)
article
Drug Target Review Neuroscience ebook 2022
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
news
Using organoids to identify drugs for autosomal dominant polycystic kidney disease
Scientists generated kidney organoids and used them to identify potential drugs to treat autosomal dominant polycystic kidney disease.
article
New immune targets to improve survival from sepsis
In a pre-clinical study, researchers from the US set out to develop a treatment for sepsis. Here, Daniel Morales-Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, describe how they utilised haematopoietic stem and progenitor cell infusion to improve the survival of mice from sepsis.
article
Using cortical spheroids to study endocannabinoids and autism spectrum disorder
The endocannabinoid system may play a role in the development of autism spectrum disorder and might be key to treating people with severe forms of the condition. In this commentary, Dr Karen Litwa, Assistant Professor at East Carolina University’s Brody School of Medicine, US explores how a bioelectronic assay is…
article
The promise of cryo-electron tomography
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Michael Grange, Tomography Group Leader from the Rosalind Franklin Institute (RFI), UK about the advantages of using cryo-electron tomography imaging.
article
Drug Target Review Stem Cells ebook
This ebook includes a piece by Daniel Morales- Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, on a stem and progenitor cell infusion to improve the survival of mice from sepsis as well as an article by Dr Karen Litwa, East Carolina University, that explores…
reference
New immune targets to improve survival from sepsis
References for ‘New immune targets to improve survival from sepsis’, in Drug Target Review Issue 2 2022.
news
Mouse study shows lab-grown, self-sustainable muscle cells could repair diseases such as muscular dystrophy
A new study highlights how scientists have successfully cultivated human muscle stem cells capable of renewing themselves and repairing muscle tissue damage in mice, findings that could lead to therapeutics to treat muscular dystrophy disorder.
article
Driving precision neurology forwards with iPSCs and new assays
Precision medicine in neurology is limited by a dearth of clinically relevant models. However, here Dr Evangelos Kiskinis, Assistant Professor at Northwestern University Feinberg School of Medicine, discusses how new technologies such as bioelectronic assays enable real-time, long-term analysis of neurological diseases in a dish, offering a pathway towards identifying…
article
Drug Target Review Assays ebook 2022
In this ebook, you can find articles on the development of novel assays and technology - download now for free!
news
“Monumental” step in using human iPSCs towards treating complication of diabetes
A new study led by the Indiana University School of Medicine showed human induced pluripotent stem cells can improve visual acuity, vascular health and other complications related to type 2 diabetes.
news
Ncardia appoints Andy Holt as Chief Commercial Officer
An iPSC technology leader taps industry veteran to drive growth in cell therapy and drug discovery markets.
news
Model to study oculocutaneous albinism eye conditions developed
The first patient-derived stem cell model to research eye conditions related to oculocutaneous albinism (OCA) has been created.
news
Ncardia secures more than $60 million to enhance and expand leading iPSC offerings
Ncardia has formed a strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services.